Dinorah Vargas-Estrada

Dr. Dinorah Vargas-Estrada

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2008 in Research in Veterinary Science
Verified
Journal Article
Closed access
DVDinorah Vargas-Estrada
Dinorah Vargas-Estrada
JGJESUS Gracia-Mora
JESUS Gracia-Mora
HSH. Sumano
H. Sumano

8 June 2012 in Acta Veterinaria Scandinavica
Verified
Journal Article
Open access
PDF file
LGLilia Gutierrez
Lilia Gutierrez
ZVZazil-Ha Velasco
Zazil-Ha Velasco
CVCarlos Vázquez
Carlos Vázquez
DVDinorah Vargas-Estrada
Dinorah Vargas-Estrada
HSHéctor Salvador Sumano-López
Héctor Salvador Sumano-López
Based on its PK/PD ratios, doxycycline hyclate (DOX-h), a time-dependant antibacterial, is ideally expected to achieve both sustained plasma drug concentrations at or slightly above the MIC level for as long as possible between dosing intervals. Pursuing this end, a poloxamer-based matrix was used to produce a long-acting injectable preparation (DOX-h-LA) and its serum concentrations vs. time profile investigated after its SC injection to dogs (≤ 0.3 mL per injection site), and results compared with the oral (PO) and IV pharmacokinetics of DOX-h, prepared as tablet or as freshly made solution. A crossover (4 x 4 x 4) study design was employed with 12 Mongrel dogs, with washout periods of 21 days, and at dose of 10 mg/kg in all cases. DOX-h-LA showed the greatest values for bioavailability (199.48%); maximum serum concentration (Cmax) value was 2.8 ± 0.3 with a time to reach Cmax (Tmax) of 2.11 ± 0.12 h and an elimination half-life of 133.61 ± 6.32 h. Considering minimum effective serum concentration of 0.5 μg/mL, a dose-interval of at least 1 week h can be achieved for DOX-h-LA, and only 48 h and 24 h after the IV or PO administration of DOX-h as a solution or as tablets, respectively. A non-painful small bulge, apparently non-inflammatory could be distinguished at injection sites. These lumps dissipated completely in 30 days in all cases.

1 August 2008 in American Journal of Veterinary Research
Verified
Journal Article
Closed access
DVDinorah Vargas-Estrada
Dinorah Vargas-Estrada
LGLilia Gutierrez
Lilia Gutierrez
IJIvan Juárez
Ivan Juárez
FGFrancisco Gonzalez
Francisco Gonzalez
HSHéctor Sumano
Héctor Sumano
Objective—To determine the pharmacokinetics after SC administration of an experimental, long-acting parenteral formulation of doxycycline hyclate in a poloxamer-based matrix and after IV and IM administration of an aqueous formulation of doxycycline hyclate in goats. Animals—30 clinically normal adult goats. Procedures—Goats were allocated to 3 groups (10 goats/group). One group of goats received doxycycline hyclate (10 mg/kg) IM, a second group received the same dosage of doxycycline hyclate IV, and the third group received the long-acting parenteral formulation of doxycycline hyclate SC. Serum concentrations of doxycycline were determined before and at various intervals after administration. Results—The long-acting parenteral formulation of doxycycline hyclate had the greatest bioavailability (545%); mean ± SD maximum serum concentration was 2.4 ± 0.95 μg/mL, peak time to maximum concentration was 19.23 ± 2.03 hours, and elimination half-life was 40.92 ± 4.25 hours. Conclusions and Clinical Relevance—Results indicated that the long-acting parenteral formulation of doxycycline hyclate distributed quickly and widely throughout the body after a single dose administered SC, and there was a prolonged half-life. Bioavailability of the longacting parenteral formulation of doxycycline hyclate after SC administration was excellent, compared with bioavailability after IV and IM administration of an aqueous formulation of doxycycline hyclate. Although no local tissue irritation and adverse effects were detected, clinical assessment of drug-residues and toxicologic evaluations are warranted before this long-acting parenteral formulation of doxycycline hyclate can be considered for use in goats with bacterial infections.

1 June 2012 in British Poultry Science
Verified
Journal Article
Closed access
LGLilia Gutierrez
Lilia Gutierrez
DVDinorah Vargas-Estrada
Dinorah Vargas-Estrada
CRC. Rosario
C. Rosario
HSHéctor Salvador Sumano-López
Héctor Salvador Sumano-López
1. The antibacterial agent doxycycline hyclate (Dox) is usually administered to broilers in drinking water or as a feed supplement. Parenteral injection is not the usual route for administration, so a long-acting formulation (Dox-LA) was tested to evaluate if serum concentrations can achieve the pharmacokinetic/pharmacodynamic (PK/PD) ratios regarded as adequate for the drug. 2. A poloxamer-based matrix was used to provide Dox-LA. Serum and tissue concentrations of Dox vs time were determined in two day-old broilers after subcutaneous (SC) injection of Dox-LA or oral administration of a single bolus of aqueous Dox (Dox-PO), at a dose of 20 mg/kg. Weight gain, feed conversion rate, haematological variables, aspartate aminotransferase and alanine aminotransferase activities, blood urea and creatinine were determined and compared for Dox-LA with Dox-PO and non-medicated controls. 3. Dox-LA had a high relative bioavailability (1200%). Maximum serum concentrations were not statistically different (5·1 ± 1·1 µg/ml for Dox-LA and 6·1 ± 1.4 µg/ml for Dox-PO), but half-life of Dox-LA was much greater than the value obtained for Dox-PO (73·0 ± 0·9 h and 2·0 ± 0·02 h, respectively). Tissue concentrations were higher, and stayed higher for longer periods in the Dox-LA group. 4. In conclusion, considering the minimum effective serum concentration against Mycoplasma spp is 0·5 µg/ml, a dose-interval of 180 h can be achieved with Dox-LA, but only for 24 h after Dox-PO. Better PK/PD ratios for Dox-LA should result in improved clinical outcomes compared with Dox-PO.

8 November 2022 in Veterinaria México OA
Verified
Journal Article
Open access
PDF file
SPSheila Irais Peña-Corona
Sheila Irais Peña-Corona
JGJose Pablo Gomez-Vazquez
Jose Pablo Gomez-Vazquez
ELEvelyn Aditi López-Flores
Evelyn Aditi López-Flores
DVDinorah Vargas-Estrada
Dinorah Vargas-Estrada
LALaura Olivia Arvizu-Tovar
Laura Olivia Arvizu-Tovar
OROrbelín Soberanis Ramos
Orbelín Soberanis Ramos
Cats and dogs have a very close relationship with humans. Currently, the overpopulation of these species in various countries worldwide has been identified as a severe public health problem. To establish effective programs for population control, it is necessary to estimate the number of cats and dogs. To our knowledge, there are no studies that assess the number of canine and feline population by state in Mexico. Therefore, this study aimed to estimate the canine and feline population living at homes using official information reported by the National Institute of Statistics, Geography and Informatics [Instituto Nacional de Estadística Geografía e Informática] through a constant-share model, a ratio extrapolation method. The estimated dog population living at homes was 42 625 010 dogs and 7 346 925 cats (at least 5.8 times less than the number of dogs). By 2022, the Mexico's estimated human:dog ratio was 2.4:1, and the human:cat ratio 17.6:1. The Estado de México had more than six million dogs and 962 177 cats. Colima had the smallest estimated dog population (245 489), and Baja California Sur the smallest estimated cat population (slightly over 30 000). Health authorities and veterinary practitioners should promote responsible ownership to increase veterinary care and control the birth of dogs and cats.

19 February 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
OEOmar Rodrigo Guadarrama Escobar
Omar Rodrigo Guadarrama Escobar
CVCassandra Araceli Valdés-Alvarez
Cassandra Araceli Valdés-Alvarez
KCKarla Stella Constantino-Gonzalez
Karla Stella Constantino-Gonzalez
PCPablo Serrano Castañeda
Pablo Serrano Castañeda
MPMa. Concepción Peña-Juárez
Ma. Concepción Peña-Juárez
JCJose Juan Escobar Chavez
Jose Juan Escobar Chavez
The short precorneal residence time of ophthalmic drops is associated with their low absorption; therefore, the development of ocular inserts capable of prolonging and controlling the ophthalmic release of drugs is an interesting option in the design and development of these drugs. A surface response design was developed, specifically the Central Composite Design (CCD), to produce ophthalmic films loaded with Dexamethasone (DEX) by the solvent evaporation method having experimental levels of different concentrations of previously selected polymers (PVP K-30 and Eudragit RS100.). Once optimization of the formulation was obtained, the in vivo test was continued. The optimal formulation obtained a thickness of 0.265 ± 0.095 mm, pH of 7.11 ± 0.04, tensile strength of 15.50 ± 3.94 gF, humidity (%) of 22.54 ± 1.7, mucoadhesion strength of 16.89 ± 3.46 gF, chemical content (%) of 98.19 ± 1.124, release of (%) 13,510.71, and swelling of 0.0403 ± 0.023 g; furthermore, in the in vivo testing the number and residence time of PMN cells were lower compared to the Ophthalmic Drops. The present study confirms the potential use of polymeric systems using PVPK30 and ERS100 as a new strategy of controlled release of ophthalmic drugs by controlling and prolonging the release of DEX at the affected site by decreasing the systemic effects of the drug.